baber/WOPTO huggingface dataset:
Patent NZ-229876-A (NZ)
Title: 6-benzofuranyl or benzothienyl substituted 3(2h)-pyridazinone derivatives and pharmaceutical compositions
Inventor: REDPATH JAMES
IPC: C07D409/04
Filed: 1989-07-07
Abstract: The invention relates to pyridazinone compounds of the general formula I: <CHEM>  wherein R<1> represents one to four substituents, which may be the same or different and are selected from H, OH, halogen, NO2, unsubstituted or C1-C4 alkyl substituted amino, C1-C4 alkyl, C1-C4 halogen substituted alkyl, O-ALK-NR<4>R<5>, C1-C4 alkoxy, whereby two substituents taken together may also represent a methylenedioxy group ;  R<2> and R<3> represent independently H or C1-C4 alkyl; R<4> and R<5> represent independently H or C1-C4 alkyl, or form together with the nitrogen a 5- or 6- membered ring;  X represents S or O;  the dotted line represents an optional bond;  and their pharmaceutically acceptable salts. The compounds according to the invention have a cardiotonic, blood platelet aggregation inhibiting, systemic vasodilator, pulmonary vasodilator, and bronchodilator activity, and more particularly they show a very potent increase of the force of the muscular contractions of the heart, reduce afterload on the heart, improve pulmonary blood flow, and improve airways ventilation.
Patent NZ-233310-A (NZ)
Title: Chewing gum containing encapsulated salt
Inventor: PATEL MANSUKH M
IPC: A23G4/00
Filed: 1990-04-12
Abstract: The use of encapsulated salts to enhance flavor and sweetness characteristics of gum is disclosed. The gum of the present invention comprises gum base, a sweetening and bulking agent, a flavoring agent, and a salt encapsulated in a manner to delay its release from the gum composition during chewing. The encapsulated salt is made by standard coating and encapsulation techniques. The gum is made by standard mixing techniques, though it is preferred to mix the encapsulated salt into the molten gum base.
Patent NZ-238163-A (NZ)
Title: Use of 4-carbamoyl-1-beta-d-ribofuranosylimidazolium-5-oleate for preparing medicaments
Inventor: SAIDA TAKAHIKO
IPC: C07H19/052
Filed: 1991-05-16
Abstract: A composition for the treatment or prevention of multiple sclerosis is disclosed. It comprises mizoribine (4-carbamoyl-1- beta -D-ribofuranosyl imidazolium-5-olate) as the effective component. It is a safe drug, exhibiting a minimal degree of side-effects, and thus can be administered over a long period of time. Administration of the drug, usually 1-20 mg/kg (body weight) per day for adults, improves the functional disturbances of multiple sclerosis
Patent NZ-241547-A (NZ)
Title: Topical analgesic composition containing ibuprofen
Inventor: DHIRAJ SHANTILAL MODY
IPC: A61K9/107
Filed: 1992-02-07
Abstract: The invention provides a topical analgesic composition comprising an oil-in-water emulsion containing about 5% to about 12% by weight of ibuprofen and about 60% to about 90% by weight of water, the oil phase of the emulsion consisting essentially of emollient constituents that do not dissolve the ibuprofen to any great extent at a pH of 4-7, the composition having a pH of about 4 to about 7.2 such that the ibuprofen is suspended in substantially solid crystalline form and the ibuprofen which is dissolved is partially in the neutral or non-charged state. The invention also includes a process for preparing this composition.
Patent NZ-247914-A (NZ)
Title: Peptides having bradykinin antagonist activity, their preparation and compositions
Inventor: FAUCHERE JEAN-LUC
IPC: C07K7/18
Filed: 1993-06-17
Abstract: Compounds of formula (I): <IMAGE> in which X, X', A1, A2, A3, A4, A5, A6, A7, A8, A 9 and Y are as defined in the description. Medications.
Patent NZ-250988-A (NZ)
Title: Powder inhaler: swirling chamber with anti-static walls
Inventor: CALVERT JOHN RICHARD
IPC: A61M15/00
Filed: 1991-06-11
Abstract: An inhaler for inhaling pulverulent medicament from within a capsule comprises a chamber 24 within which the capsule is free to rotate while having its longitudinal axis in the median plane of the chamber and thus generally parallel to the front and rear walls 29 and 30 of the chamber, by virtue of the fact that the spacing between said front and rear walls is less than the axial length of the capsule but just greater than the diameter of the capsule. The device includes pins 21 serving as opening means to pierce the ends of the capsule while it is seated in a recess 25, whereupon the retraction of the pins 21 allows the capsule to be entrained into swirling airflow in the chamber 24 during inhalation of air through air inlets 26 and out through a mouthpiece nozzle 27. <IMAGE>   <IMAGE>
Patent NZ-251000-A (NZ)
Title: Wet process board manufacture characterised in that binder is added to the fibrous material prior to dewatering and pressing
Inventor: FLODMAN LEIF
IPC: D21J1/00
Filed: 1993-03-09
Abstract: In a process for making board according to the wet method, a stock is prepared from fibres produced from a fibrous raw material, and a binder is added prior to dewatering and pressing. The process is distinguished by adding the binder to the fibres before the preparation of the stock. The binder may be a water-soluble binder which is precipitated and fixed to the fibres by acidification. Acidification may take place in connection with the preparation of the stock or prior thereto as well as prior to the addition of the binder. The binder can be added to the fibres in the blow line from the defibrator for producing the fibres from the fibrous raw material, or it may be added to the fibres before the defibrator.
Patent NZ-254577-A (NZ)
Title: Isolated promoter element for enhancement of expression from brassica and its use when combined with a structural gene for confering immunity and/or resistance to disease in plant roots
Inventor: BASZCZYNSKI CHRIS J
IPC: C12N15/82
Filed: 1993-07-12
Abstract: The present invention is directed to an isolated promoter element that exhibits root abundant expression in Brassica sp. The promoter element has particular utility in driving the transcription of heterologous structural proteins that confer disease immunity or resistance to disease susceptible roots. The word "disease" encompasses any adverse condition caused to a plant by an organism other than itself, such as fungi, bacteria, and insects. Plasmids incorporating the promoter are disclosed.
Patent NZ-262255-A (NZ)
Title: 4-hydroxycoumarin derivatives and homologues thereof; pharmaceutical compositions
Inventor: ANDERSON DAVID JOHN
IPC: C07D409/06
Filed: 1994-02-03
Abstract: PCT No. PCT/US94/00938 Sec. 371 Date Aug. 4, 1995 Sec. 102(e) Date Aug. 4, 1995 PCT Filed Feb. 3, 1994 PCT Pub. No. WO94/18188 PCT Pub. Date Aug. 18, 1994The present invention relates to compounds of formula I which are 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl[b]pyran-2-ones useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus.    <IMAGE>  I  Wherein R10 and R20 taken together are:    <IMAGE>  II   <IMAGE>  III
Patent NZ-271025-A (NZ)
Title: Process for making steel and hydraulically active binders using slags rich in iron oxide
Inventor: EDLINGER ALFRED
IPC: C04B7/147
Filed: 1994-08-24
Abstract: The process for making steel and hydraulically active binders uses slags rich in iron oxide, such as steel slag, as oxidizing agent for carbon in pig iron. The slag is reduced, yielding a type of blast furnace slag with improved hydraulic properties.
Patent NZ-331360-A (NZ)
Title: an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex
Inventor: AKITA ROBERT
IPC: C12P21/08
Filed: 1997-03-07
Abstract: An antibody, which binds to ErbB3 protein and reduces heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell, which expresses ErbB2 and ErbB3, is claimed. The antibody, as defined above, can also have the ability to increase the binding affinity of heregulin for ErbB3 protein and/or to reduce heregulin-induced ErbB2 activation in a cell, which expresses ErbB2 and ErbB3. A cell line producing the antibody as defined above is claimed. The antibody is used in a method of determining the presence of ErbB3 proteins.
Patent NZ-335697-A (NZ)
Title: A pump device
Inventor: LUNDGREN LARS-OLOF
IPC: F04F/
Filed: 1997-10-23
Abstract: A pump device comprises a supply tube (1) for a liquid with a relatively low head, an accumulator (3) connected to the same via a non-return valve (2), an outlet tube (4) from the accumulator for liquid with a relatively high head, and an outlet valve, provided at the supply tube (1) after the accumulator.  The outlet valve opens and shuts an outlet at the supply tube (1).  The outlet valve comprises a damper (6) movable between a position, in which the opening is left open, and a position, in which the opening is closed.
Patent NZ-337771-A (NZ)
Title: Storage device for documents having detachable receptacles
Inventor: ISSERSTEDT ROBERT
IPC: A47B63/02
Filed: 1998-02-13
Abstract: Provided is a storage device comprises a support structure (1) carrying a plurality of receptacle (11) such as document pouches arranged in a longitudinal series.  The support structure has a pair of spaced side members (4, 5) which are foldable so that the pouches may be arranged either in a closed up array or suspended in an opened out array.  Support members (6) extend laterally between the side members (4, 5) and the pouches (11) are releasably supported on the support members and extend through gaps (3) between the support members.  The pouches have closure flaps (15) which can be folded backwards over the support members (6) to suspend the pouches from them. A locating tab (10) may pass through an aperture (16) in the pouch and be folded over to hold the pouch to the support member (6).  The support structure is made from a sheet of material provided with apertures (3) which define the side and support members (4, 5, 6).
Patent NZ-501954-A (NZ)
Title: Hybrid seed and transformed plants expressing an exogenous nucleotide sequence operably linked to a male tissue-preferred regulatory region
Inventor: ALBERTSEN MARC C
IPC: C12N15/09
Filed: 1998-06-19
Abstract: An isolated nucleic acid sequence encoding the Ms45 male tissue-preferred regulatory region is provided. This male tissue-preferred regulatory region may be used in mediating fertility, such as in the production of hybrid seed in a male sterility system. The Ms45 male tissue-preferred regulatory region can be operably linked with exogenous genes; such as those encoding cytotoxins, complementary nucleotidic units and inhibitory molecules; and used to express the gene in a male tissue-preferred manner in transformed plants.
Patent NZ-504458-A (NZ)
Title: Use of a mixture of a diol and an alpha-hydroxy acid in a semi-occluding vehicle for the treatment of hyperkeratotic skin diseases
Inventor: GANEMO AGNETA
IPC: A61K47/00
Filed: 1998-11-25
Abstract: The use of compositions containing a mixture of a diol and an alpha-hydroxy acid in a semi-occluding vehicle for the topical treatment of hyperkeratotic skin diseases is disclosed.
Patent NZ-506607-A (NZ)
Title: Interaction between software and input device
Inventor: KLITSNER DAN
IPC: G06F3/023
Filed: 1999-02-04
Abstract: Interaction between a user and a computer (105) is encouraged by using an input device (135) including actuators (140) formed as three-dimensional representations of physical objects. Software running on the computer (105) receives an input signal generated by actuation of a particular actuator (140) by the user, and provides feedback to the user. The feedback is consistent with the particular physical object represented by the particular actuator (140). For example, if the particular actuator (140) represents a saw (215), the software causes the computer (105) to display an audio-visual sequence representative of movement of the saw (215).
Patent NZ-512207-A (NZ)
Title: Process for producing quinolinecarbaldehyde
Inventor: MATSUMOTO HIROO
IPC: C07D215/14
Filed: 1999-11-29
Abstract: A process for producing 2-cyclopropyl-4-(4-fluorophenyl)-quinoline-3-carbaldehyde of the formula (III).  This compound is useful as an intermediate for the synthesis of an HMG-CoA reductase inhibitor as a cholesterol lowering drug.
Patent NZ-513538-A (NZ)
Title: Pharmaceutical composition associated with hydrogel particles for administration by transdermal delivery from a needless syringe
Inventor: O'CONNOR BARBARA H
IPC: A61K48/00
Filed: 2000-02-03
Abstract: Compositions formed from the combination of an active substance with a hydrogel carrier moiety are provided. The compositions are suitable for use in high-velocity transdermal particle injection techniques. Methods of providing the new compositions are also provided. In addition, methods for administering pharmacologically active agent to a subject are provided. These methods are useful for delivering drugs, biopharmaceuticals, vaccines and diagnostic agents. The results of the study for 4% agarose beads are presented in the figure. The maximum % insulin loading by theoretical calculation in a single loading step is 37.5% for 4% agarose beads, compared with 22.3% for 8% agarose beads (not shown). As can be seen by these results, the multiple (iterative) loading method described herein is suitable to provide for extremely high drug loading per particle on a dry weight basis.
Patent NZ-521476-A (NZ)
Title: Microparticles of glycopyrrolate for the treatment of respiratory diseases
Inventor: BANNISTER ROBIN MARK
IPC: A61K31/46
Filed: 2001-04-09
Abstract: A dry powder formulation for pulmonary delivery or inhalation, which contain microparticles of glycopyrrolates is disclosed. To improve the moisture resistance, and to also improve the storage stability of this formulation, magnesium stearate is used in this formulation. One of the features of this dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.
Patent NZ-524517-A (NZ)
Title: Leaf spring eye wrap scarf gap cover component
Inventor: DANKOW MARK WILLIAM
IPC: B60G11/12
Filed: 2001-08-07
Abstract: A suspension system component for use in association with a leaf spring eye wrap of a leaf spring is shown to include a generally rigid planar base portion (52) and a generally rigid scarf gap cover portion (58) extending from the base portion in a direction generally normal to the base portion. The scarf gap cover portion includes first and second cover portions (62, 64) extending in different planes and adjoined at a seam (66). The component further includes a generally rigid first stop portion (54) formed as a peg-like structure extending from the base portion in the same direction as the scarf gap cover portion. The component also includes a generally rigid second stop portion (56) formed as a curved engagement surface extending from the base portion in that same direction.
Patent NZ-525687-A (NZ)
Title: Fertilizer
Inventor: GREEN KERRY
IPC: C05G3/00
Filed: 2001-11-07
Abstract: A fertilizer comprising: a fast uptake form of a micronutrient or macronutrient; and a slow uptake form of a micronutrient or macronutrient, wherein the fast uptake form is in a form that is absorbed more readily by a plant than the slow uptake form and the fast uptake form is a sulfate, nitrate or acid form of the micronutrient or macronutrient and the slow uptake form is a sulfate, chloride, oxide, tetrahydrate, or octaborate form of the micronutrient or macronutrient, said slow uptake form being coated such that the slow uptake form and the fast uptake form can be mixed together in the fertilizer.
Patent NZ-526666-A (NZ)
Title: Impeller drive for a jet propulsion unit
Inventor: DAVIES BARRY JOHN
IPC: B63H11/08
Filed: 2003-07-14
Abstract: A water propulsion unit comprising an intake housing, a pump housing, an outlet housing, an upstream impeller and a downstream impeller, said upstream and downstream impellers being spaced apart and located within the pump housing between the intake housing and the outlet housing, each impeller including a series of impeller blades extending radially from a central boss, the blades of the upstream impeller being of opposite pitch to the blades of the downstream impeller; wherein said impellers are mounted on and, in use, driven by shafts so as to be co-axial with each other, within the pump housing; wherein the impellers are configured such that in use one of the impellers will impart less energy passing that impeller than the remaining impeller; and the upstream impeller in use will create a drop in pressure upstream of said upstream impeller and impart a rapid change in velocity to the water as it passes over the blades.
Patent NZ-526868-A (NZ)
Title: Substituted alkylamine derivatives and methods of use for treating cancer and angiogenesis related disorders
Inventor: CHEN GUOQING
IPC: A61K31/4709
Filed: 2002-01-11
Abstract: Selected heterocyclic compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, that are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases are disclosed. Pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions such as cancer, and processes for making such compounds as well as to intermediates useful in such processes are also disclosed.
Patent NZ-527579-A (NZ)
Title: Framed security closure
Inventor: STRETCH STEWART
IPC: E06B9/01
Filed: 2003-08-12
Abstract: A security closure comprising a frame where the frame is adapted to be mounted across an opening, a perforate sheet element supported at its side edges by the frame to close the frame wherein at least some of the side edges of the sheet element are formed with a lip, the frame formed with a recess having an opening directed inwardly with respect to the closure, the side edges of the sheet element being received within the recess such that the lip is located within the recess, an elongate locking member received and fixed in the recess outward of the lip, said locking member being clampingly engaged with the sheet material and the recess.
Patent NZ-527911-A (NZ)
Title: Control of powered furniture
Inventor: COLCLOUGH STEPHEN HENRY
IPC: A47C17/04
Filed: 2001-04-24
Abstract: A furniture arrangement (typically a chair or bed) powered to be movable between a first and a second configuration including a detector arrangement (1) for detecting the presence of foreign bodies in the vicinity of the furniture piece, the detector arrangement (1) being connected to a controller arranged to modify the output of the driver driving the furniture where a foreign body is detected. The detector arrangement (1) includes an elongate flexible detector disposed to extend continuously around a base, or base mount or plinth (14), of said furniture so as to have elongate portions extending in substantially mutually perpendicular directions.
Patent NZ-531590-A (NZ)
Title: Human monoclonal antibody
Inventor: LOGTENBERG TON
IPC: A61K39/395
Filed: 2000-12-21
Abstract: A human monoclonal antibody capable of binding to human Ep-CAM is described that comprises a heavy chain CDR3 region having the amino acid sequence DPFLHY. Preferably the antibody is affinity matured and has an affinity constant for human Ep-CAM that is lower than 5 nM. The antibody can be used in the manufacture of a medicament for the treatment of a tumor such as colon carcinoma.
Patent NZ-551560-A (NZ)
Title: Actuator with memory part for building management system
Inventor: JAHN GERHARD
IPC: H05B37/02
Filed: 2005-05-27
Abstract: A building management system for controlling several actuators that are disposed in a distributed manner is disclosed. The building management system is composed of a central control unit (2) and at least one actuator (10) that is triggered by the central control unit (2). The actuator (10) is provided with a control device (11) which is configured to receive control commands from the central control unit (2) and operate the actuator (10) in accordance with the control commands, and a memory part (13) for storing functionally relevant data. The memory part (13) is or can be separated from the control device (11) and is constituted by an exchangeable memory element. The actuator or the control device has an insertion for the exchangeable memory element.
Patent NZ-553341-A (NZ)
Title: 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
Inventor: HEIDELBAUGH TODD M
IPC: A61K31/4174
Filed: 2005-09-07
Abstract: Disclosed are 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones compounds of formula (I) where the variables are disclosed in the specification. Also disclosed is the pharmaceutical composition and use of the compounds for the manufacture of a medicament to treat chronic pain, visceral pain, neuropathic pain, corneal pain, glaucoma, elevated intraocular pressure, ischemic neuropathies, neurodegenerative diseases, diarrhea, nasal congestion, muscle spasticity, diuresis, withdrawal syndromes, neurodegenerative diseases, optic neuropathy, spinal ischemia, stroke, memory and cognition deficits, attention deficit disorder, psychoses, manic disorders, anxiety, depression, hypertension, congestive heart failure, cardiac ischemia, arthritis, spondylitis, gouty arthritis, osteoarthritis, juvenile arthritis, autoimmune diseases, lupus erythematosus, chronic gastrointestinal inflammations, Crohn's disease, gastritis, irritable bowel syndrome (IBS), functional dyspepsia and ulcerative colitis.
Patent NZ-554556-A (NZ)
Title: Halogen substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepines
Inventor: KNUST HENNER
IPC: C07D487/14
Filed: 2005-10-11
Abstract: Disclosed are halogen substituted imidazo[1,5-a][1,2,4]triazolo[1,5--d][1,4]benzodiazepine derivatives of formula (I), and their pharmaceutically acceptable acid addition salts. The compounds may be used for the treatment of cognitive disorders, anxiety, Alzheimer's disease and schizophrenia.
Patent NZ-556461-A (NZ)
Title: Genetic variants of vkorc1 predicting warfarin sensitivity
Inventor: CHEN YUAN-TSONG
IPC: C12Q1/68
Filed: 2005-12-21
Abstract: Disclosed is a method of determining the dose range of warfarin for a subject, comprising investigating the single nucleotide polymorphism (SNP) at the 3673 position of SEQ ID NO: 1 in the subject, determining whether the subject is warfarin sensitive or resistant based on the SNP at the 3673 position, wherein homozygous AA, heterozygous AG, and homozygous GG at this position indicate that the patient is warfarin sensitive, intermediate sensitive, and resistant, respectively; and predicting a warfarin dosage range based on the warfarin sensitivity/resistance of the subject.